NCT04108481 2025-03-28
iRE-C
University of Iowa
Phase 1 Terminated
Clinical Trials
7 trialsNCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02777710 2021-09-05
MEDIPLEX
Centre Leon Berard
Phase 1 Completed
NCT03005002 2019-12-26
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
City of Hope Medical Center
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed